Introduction
HIV therapeutics have undergone a substantial evolution since its inception over three decades ago. From the first controversial FDA-approved drug, Retrovir ((AZT)) to today's newest life-saving combination antiretroviral therapies, HIV therapy has seen incredible progress. Despite such progress, however, there is still considerable research and work that needs to be done in the field. HIV's ability to conceal itself in inaccessible viral reservoirs and its ability to outclass even the most sophisticated antiretroviral combinations have remained key obstacles to effective and long-term viral control. New research has led Gilead Sciences (GILD), Inc.,